58 results
8-K
EX-99.1
PTCT
PTC Therapeutics Inc
25 Jan 24
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
4:06pm
of the patient community and expert physicians, will be devastating for children and young men in Europe for whom no other disease-modifying therapies
8-K
EX-99.1
y3pi6vt9 0h
19 Jul 23
Regulation FD Disclosure
12:00pm
8-K
EX-99.2
bpkd sqik73dd0l2mdht
17 May 23
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
7:04am